Journal article

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.

Jason Grebely, Brian Conway, Evan B Cunningham, Chris Fraser, Alberto Moriggia, Ed Gane, Catherine Stedman, Curtis Cooper, Erika Castro, Patrick Schmid, Kathy Petoumenos, Behzad Hajarizadeh, Phillipa Marks, Amanda Erratt, Olav Dalgard, Karine Lacombe, Jordan J Feld, Julie Bruneau, Jean-Pierre Daulouede, Jeff Powis Show all

Int J Drug Policy | Published : 2018


BACKGROUND: Direct-acting antiviral therapy for hepatitis C virus (HCV) infection is safe and effective, but there are little data among people who have recently injected drugs. This study evaluated the efficacy, and safety of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for chronic HCV genotype (G) 1 among people with recent injecting drug use and/or receiving OST. METHODS: D3FEAT is an international open-label study that recruited treatment-naïve participants with recent injecting drug use (previous 6 months) and/or receiving OST with chronic HCV G1 infection between June 2016 and February 2017 in seven countries. Participants received paritaprevir/ritonavir, omb..

View full abstract

University of Melbourne Researchers